Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1929 1
1930 1
1934 6
1935 2
1936 6
1946 1
1950 1
1951 1
1953 1
1954 1
1955 1
1956 1
1957 1
1958 2
1959 6
1961 1
1962 1
1963 1
1964 5
1965 9
1966 3
1967 2
1968 1
1969 3
1970 4
1972 1
1973 5
1974 2
1975 2
1976 7
1977 5
1978 9
1979 6
1980 3
1981 7
1982 11
1983 14
1984 19
1985 29
1986 26
1987 35
1988 38
1989 28
1990 36
1991 31
1992 49
1993 37
1994 43
1995 28
1996 45
1997 50
1998 49
1999 56
2000 69
2001 85
2002 76
2003 120
2004 130
2005 153
2006 203
2007 237
2008 293
2009 314
2010 440
2011 445
2012 569
2013 669
2014 713
2015 827
2016 838
2017 963
2018 1087
2019 1243
2020 1480
2021 1755
2022 1151
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

13,065 results
Results by year
Filters applied: . Clear all
Page 1
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy.
Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, Zhou F, Jin Z, Huang J, Zhou L, Hu C, Wang X, Zhang J, Ba Y, Gong Y, Zeng X, Zeng D, Su X, Alexander PB, Wang L, Wang L, Wan YY, Wang XF, Zhang L, Li QJ, Zhu B. Long H, et al. Among authors: hu c. Cancer Cell. 2022 Jun 13;40(6):674-693.e7. doi: 10.1016/j.ccell.2022.04.018. Epub 2022 May 19. Cancer Cell. 2022. PMID: 35594863
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, Louca P, May A, Figueiredo JC, Hu C, Molteni E, Canas L, Österdahl MF, Modat M, Sudre CH, Fox B, Hammers A, Wolf J, Capdevila J, Chan AT, David SP, Steves CJ, Ourselin S, Spector TD. Menni C, et al. Among authors: hu c. Lancet. 2022 Apr 23;399(10335):1618-1624. doi: 10.1016/S0140-6736(22)00327-0. Epub 2022 Apr 7. Lancet. 2022. PMID: 35397851 Free PMC article.
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. Lu S, et al. Among authors: hu c. J Clin Oncol. 2022 May 17:JCO2102641. doi: 10.1200/JCO.21.02641. Online ahead of print. J Clin Oncol. 2022. PMID: 35580297
Single-Molecule Mechanochemical Sensing.
Hu C, Tahir R, Mao H. Hu C, et al. Acc Chem Res. 2022 May 3;55(9):1214-1225. doi: 10.1021/acs.accounts.1c00770. Epub 2022 Apr 14. Acc Chem Res. 2022. PMID: 35420417
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: hu c. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
13,065 results
You have reached the last available page of results. Please see the User Guide for more information.